TARS1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19792912	0.54	10/20
SCHEMBL18019182	0.52	10/20
SCHEMBL19792918	0.59	9/20
SCHEMBL18019151	0.46	9/20
SCHEMBL18019111	0.49	8/20
SCHEMBL17977180	0.48	8/20
SCHEMBL19792909	0.48	8/20
SCHEMBL18019112	0.47	8/20
SCHEMBL19792915	0.47	8/20
SCHEMBL18019152	0.44	8/20
SCHEMBL18019181	0.54	7/20
SCHEMBL19792911	0.52	7/20
SCHEMBL19792916	0.49	7/20
SCHEMBL19792917	0.48	7/20
SCHEMBL18019156	0.47	7/20
SCHEMBL18019191	0.47	7/20
SCHEMBL18019150	0.46	7/20
SCHEMBL18019157	0.46	7/20
SCHEMBL18019193	0.46	7/20
SCHEMBL18019192	0.44	7/20

Clinical trials — most relevant to TARS1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia	nan	RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy.	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Identification of a New Gene Involved in Hereditary Lipodystrophy	nan	COMPLETED
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TARS1 binder may also engage these)

Protein	Name	Similarity
Q5XHY5	—	1.000	Q5XHY5 →
Q3ZBV8	—	1.000	Q3ZBV8 →
Q9D0R2	—	1.000	Q9D0R2 →
Q0V9S0	—	0.998	Q0V9S0 →
O04630	—	0.997	O04630 →
F4IFC5	—	0.997	F4IFC5 →
P52709	—	0.996	P52709 →
A2RTX5	—	0.994	A2RTX5 →
P04801	—	0.994	P04801 →
Q8BLY2	—	0.994	Q8BLY2 →
P87144	—	0.994	P87144 →
Q54J66	—	0.992	Q54J66 →
Q73RR5	—	0.987	Q73RR5 →
Q32FI0	—	0.986	Q32FI0 →
Q87Q70	—	0.986	Q87Q70 →
A6L9S2	—	0.986	A6L9S2 →
Q1C728	—	0.986	Q1C728 →
C0RJ44	—	0.986	C0RJ44 →
Q8NNC6	—	0.986	Q8NNC6 →
A9N243	—	0.985	A9N243 →
B5BA42	—	0.985	B5BA42 →
Q8Z6I2	—	0.985	Q8Z6I2 →
C4ZYI1	—	0.985	C4ZYI1 →
Q0THB0	—	0.985	Q0THB0 →
B7MVJ7	—	0.985	B7MVJ7 →
A1ABQ2	—	0.985	A1ABQ2 →
B5QVW8	—	0.985	B5QVW8 →
Q82BR9	—	0.985	Q82BR9 →
B8CME8	—	0.985	B8CME8 →
A8H4U6	—	0.985	A8H4U6 →